Lilly expands open-innovation efforts with new drug discovery platform
September 21, 2011 By Peter Mansell
ABSTRACT:
This study describes the innovation techniques that Eli Lily has implemented in its June 2009 Phenotypic Drug Discovery (PD2), and describing their expanded open-innovation platform. This process now permits outside scientists to deposit molecules and have them tested free of charge. This new venture is called TD(2). Eli Lily is particularly focused on the fields of endocrinology, neuroscience, oncology and cardiovascular diseases. The Open-Innovation Drug Discovery Innovation combines the existing PD2 platform with three new programs.
[READ THE FULL ARTICLE]